Lakshmi Priya and Ashalatha Radhakrishnan*

Comprehensive Centre for Sleep disorders, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India

*Corresponding Author:Ashalatha Radhakrishnan, Comprehensive Centre for Sleep disorders, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.

Received: March 01, 2022; Published: March 25, 2022

Abstract

‘Narcolepsy’ comes from French narcolepsie, which was first used by French physician Jean-Baptiste Edouard Gelineau in 1880. This French word came from a combination of Greek narke, meaning stupor or numbness, and lepsis, meaning a seizure. The tetrad of narcolepsy symptoms proposed by Yoss., et al. in 1957 consists of excessive daytime somnolence, hypnogogic hallucinations, sleep paralysis and cataplexy [1]. Narcolepsy is a chronic neurologic condition due to dysregulation of sleep wake cycle, affecting 1 in 3000 individuals with a bimodal peak of incidence at 15 and 36 years of age [2]. However, there is a diagnostic delay inspite of early age of onset partly due to limited awareness of this entity among physicians and partly due to the associated comorbidity burden among patients with Narcolepsy [3].

Keywords: Narcolepsy; Cataplexy; Hypocretin; SOREMPs; MSLT

References

1. Yoss RE and Daly DD. “Criteria for the diagnosis of the narcoleptic syndrome”. Proceedings of the staff meetings of the Mayo Clinic 32 (1957): 320-328.
2. Dauvilliers Y., et al. “Age at onset of narcolepsy in two large populations in France and Quebec”. Neurology 57 (2001): 2029-2033.
3. Thorpy MJ and Krieger AC. “Delayed diagnosis of narcolepsy: characterization and impact”. Sleep Medicine 5 (2014): 502-507.
4. International Classification of Sleep Disorders. Diagnostic and coding manual. 2^nd edition”. Westchester, IL, USA: American Academy of Sleep Medicine (2005).
5. Nishino S., et al. “Hypocretin (orexin) deficiency in human narcolepsy”. Lancet 9197 (2000): 39-40.
6. Andlauer O., et al. “Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy”. Sleep9 (2012): 1247-1255F.
7. Andlauer O., et al. “Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency”. JAMA Neurology 7 (2013): 891-902.
8. International Classification of Sleep Disorders. Diagnostic and coding manual. 2^nd edition”. Westchester, IL, USA: American Academy of Sleep Medicine (2005).
9. Leschziner G. “Narcolepsy: a clinical review”. Practical Neurology 5 (2014): 323-331.
10. Nightingale S., et al. “The association between narcolepsy and REM behavior disorder (RBD)”. Sleep Medicine 3 (2005): 253-258.
11. Sturzenegger C and Bassetti CL. “The clinical spectrum of narcolepsy with cataplexy: a reappraisal”. Journal of Sleep Research 4 (2004): 395-406.
12. Naumann A., et al. “Cognitive deficits in narcolepsy”. Journal of Sleep Research 3 (2006): 329-338.
13. Ohayon MM. “Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population”. Sleep Medicine 6 (2013): 488-492.
14. Buskova J., et al. “Olfactory dysfunction in narcolepsy with and without cataplexy”. Sleep Medicine 11 (2010): 558-561.
15. Nishino S and Kanbayashi T. “Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system”. Sleep Med Rev 4 (2005): 269-310.
16. Littner MR., et al. Standards of Practice Committee of the American Academy of Sleep Medicine. “Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test”. Sleep1 (2005): 113-121.
17. Mignot E., et al. “Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults”. Brain 129 (2006): 1609-1023.
18. Bourgin P., et al. “CSF hypocretin-1 assessment in sleep and neurological disorders”. Lancet Neurology 7 (2008): 649-662.
19. Tafti M., et al. “DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe”. Sleep 37 (2014): 19-25.
20. Thannickal TC., et al. “Reduced number of hypocretin neurons in human narcolepsy”. Neuron3 (2000): 469-474.
21. Thannickal TC., et al. “Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy”. Sleep8 (2009): 993-998. doi: 10.1093/sleep/32.8.993. PMID: 19725250; PMCID: PMC2717206
22. Tafti M., et al. “DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe”. Sleep1 (2014): 19-25. doi: 10.5665/sleep.3300. PMID: 24381371; PMCID: PMC3865351.
23. Mahlios J., et al. “The autoimmune basis of narcolepsy”. Curr Opin Neurobiol 5 (2013): 767-773. doi: 10.1016/j.conb.2013.04.013. Epub 2013 May 29. PMID: 23725858; PMCID: PMC3848424.
24. Broughton RJ., et al. “Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy”. Neurology2 (1997): 444-451. doi: 10.1212/wnl.49.2.444. PMID: 9270575.
25. lazzi G., et al. “Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy”. J Neurol 255 (2008): 1549-1554.
26. Mieda M and Sakurai T. “Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status”. CNS Drugs 27 (2013): 83-90.
27. De la Herran-Arita AK and Garcia-Garcia F. “Current and emerging options for the drug treatment of narcolepsy”. Drugs 73 (2013): 1771-1781.
28. Pedroso JL., et al. “Gelastic cataplexy as the first neurologic manifestation of Niemann-Pick type C”. Neurology 79 (2012): e189.
29. Nelson GB and Hahn JS. “Stimulus-induced drop episodes in Coffin-Lowry syndrome”. Pediatrics 111 (2003): e197-202.
30. Dreissen YE and Tijssen MA. “The starle syndromes: physiology and treatment”. Epilepsia S7 (2012): 3-11.

Citation

Citation: Lakshmi Priya and Ashalatha Radhakrishnan. “Approach to Narcolepsy - A Rare but Potentially Treatable Sleep Disorder!". Acta Scientific Neurology 5.4 (2022): 19-25.

Copyright

Copyright: © 2022 Lakshmi Priya and Ashalatha Radhakrishnan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.